Clinical Trial

A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a randomized, open-label, multi-center, global phase II/III clinical study to evaluate the efficacy and safety of HLX43 monotherapy or HLX43 in combination with HLX07 vs. docetaxel in the treatment of advanced squamous NSCLC after failure of first-line treatment.
Protocol Amendment History 2 changes
critical Trial status changed: Enrolling by Invitation → Recruiting 2026-06-02
critical Trial status changed: Not Yet Recruiting → Enrolling by Invitation 2026-05-30
Trial Details
NCT Number NCT07459751
Lead Sponsor Shanghai Henlius Biotech
Conditions Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Enrollment 706 participants
Start Date 2026-05-27
Primary Completion 2030-01-15 (estimated)
Study Completion 2030-01-15 (estimated)
Updated on ClinicalTrials.gov 2026-06-01